Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

NCT03777410 is registered in ClinicalTrials.gov with Travera Inc as lead sponsor.

NCT NCT03777410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03777410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
Lead sponsor
Travera Inc
Phase
Observational
Overall status
Terminated
Start date
February 11, 2019
Completion date
June 30, 2024
Enrollment
33 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse